Leo Spaccavento, MD
Interventional Cardiology · Las Vegas, NVNPI 1982793287
Payments from drug & device makers
Across 401 payments — averaging $32.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Novartis$1K
- Medtronic$568
- Johnson & Johnson$545
- E.r. Squibb & Sons, L.L.C.$518
- Cvrx, Inc.$464
- plus $4K from 28 others
What the payments were for
- Food & beverage$9,647100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $5,495 |
| Novartis | 64 | $1,434 |
| Medtronic | 6 | $568 |
| Johnson & Johnson | 42 | $545 |
| E.r. Squibb & Sons, L.L.C. | 33 | $518 |
| Cvrx, Inc. | 8 | $464 |
| Amgen | 37 | $463 |
| Boehringer Ingelheim | 16 | $396 |
| Pfizer | 20 | $294 |
| Actelion Pharmaceuticals US, Inc. | 12 | $290 |
| Sanofi-aventis U.S. LLC | 14 | $277 |
| Novo Nordisk | 12 | $264 |
| Bayer | 12 | $234 |
| Merck | 10 | $189 |
| Boston Scientific | 7 | $173 |
| Philips North America LLC | 6 | $150 |
| Esperion Therapeutics, Inc. | 7 | $147 |
| Bridgebio Pharma, Inc. | 5 | $136 |
| Merit Medical Systems Inc | 1 | $110 |
| Amarin Pharma, Inc. | 7 | $101 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $91 |
| Lexicon Pharmaceuticals, Inc. | 4 | $82 |
| Kowa Pharmaceuticals America, Inc. | 4 | $67 |
| Irhythm Technologies, Inc. | 2 | $47 |
| Edwards Lifesciences | 2 | $46 |
| Scpharmaceuticals Inc. | 2 | $45 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Impulse Dynamics (USA) Inc. | 1 | $32 |
| AstraZeneca | 2 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Astellas Pharma US Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CARDIOMEMS$1,109
- ENTRESTO$375
- Barostim Neo System$321
- Cobalt$158
- LINQ II$157
- Attain$149
- Prelude Introducers$110
- Rad Bd, Rad Bd Xtra, Rad Trac$110
How this compares
$12,852 in reported general payments places this provider in the 55th percentile of 62 interventional cardiology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 403 | $468,056 |
| XareltoRivaroxaban | 326 | $327,393 |
| EntrestoSacubitril/Valsartan | 195 | $240,664 |
| Repatha SureclickEvolocumab | 142 | $109,068 |
| JardianceEmpagliflozin | 53 | $55,929 |
| MultaqDronedarone Hcl | 21 | $44,343 |
| Repatha SyringeEvolocumab | 41 | $37,747 |
| BrilintaTicagrelor | 37 | $37,130 |
| KerendiaFinerenone | 15 | $17,263 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $15,141 |
| Praluent PenAlirocumab | 11 | $12,504 |
| Ezetimibe | 416 | $10,059 |
| Amiodarone Hcl | 292 | $7,286 |
| Midodrine Hcl | 53 | $6,633 |
| Metoprolol Succinate | 477 | $6,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $294 | $468,056403 claims |
| Johnson & JohnsonXarelto | $545 | $327,393326 claims |
| NovartisEntresto | $1,434 | $240,664195 claims |
| Boehringer IngelheimJardiance | $396 | $55,92953 claims |
| Sanofi-aventis U.S. LLCMultaq | $277 | $44,34321 claims |
| AstraZenecaBrilinta | $30 | $37,13037 claims |
| BayerKerendia | $234 | $17,26315 claims |
| Esperion Therapeutics, Inc.Nexlizet | $147 | $15,14113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 62 interventional cardiology providers in Nevada.
Other interventional cardiology in Las Vegas
- Cres MirandaLas Vegas$660K
- Adrian Mercado-AlamoLas Vegas$118K
- Nayab ZafarLas Vegas$102K
- William ChuLas Vegas$75K
- Neville MistryLas Vegas$40K
- Leon VarjabedianLas Vegas$34K
- Moniz DawoodLas Vegas$29K
- Andrew LuxhojLas Vegas$22K
- Mohi AlkadriLas Vegas$20K
- John BedottoLas Vegas$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.